Lv1
40 积分 2025-03-19 加入
Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens
2个月前
已完结
Novel therapies for acute myeloid leukemia. Does age still matter?
2个月前
已完结
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
2个月前
已完结
Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial
2个月前
已关闭
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial
3个月前
已完结
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis
4个月前
已完结
老年急性髓系白血病的治疗
4个月前
已完结
Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations
4个月前
已关闭
Venetoclax plus ‘2 + 5’ modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single‐centre retrospective analysis
4个月前
已完结
皖公网安备34019202002308
